

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): **May 14, 2021**

**CELLECTAR BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**1-36598**  
(Commission  
File Number)

**04-3321804**  
(I.R.S. Employer  
Identification No.)

**100 Campus Drive, Florham Park, New Jersey 07932**  
(Address of principal executive offices, and zip code)

**(608) 441-8120**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.00001	CLRB	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**ITEM 7.01 REGULATION FD DISCLOSURE**

On May 14, 2021, we issued a press release announcing that we will participate and be available for 1x1 meetings at the Oppenheimer Rare & Orphan Disease Summit to be held May 21, 2021. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits

Number	Title
<u>99.1</u>	<u>Press release dated May 14, 2021, titled "Collectar to Participate at the Oppenheimer Rare &amp; Orphan Disease Summit on May 21, 2021"</u>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 14, 2021

**CELLECTAR BIOSCIENCES, INC.**

By: /s/ Dov Elefant

Name: Dov Elefant

Title: Chief Financial Officer



## Collectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021

FLORHAM PARK, N.J., May 14, 2021 -- Collectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the company will participate and be available for 1x1 meetings at the following upcoming conference:

### Oppenheimer Rare & Orphan Disease Summit

Date: May 21, 2021  
Time: On demand presentation for registered participants  
Available for 1x1 meetings  
Webcast: To register, click on the link [HERE](#)

A replay of the presentation will be available on the [Events page](#) of the company website.

### About Collectar Biosciences, Inc.

Collectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The company's product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit [www.collectar.com](http://www.collectar.com) or join the conversation by liking and following us on the company's social media channels: [Twitter](#), [LinkedIn](#), and [Facebook](#).

### Contacts

#### Investors:

Monique Kosse  
Managing Director  
LifeSci Advisors  
212-915-3820  
[monique@lifesciadvisors.com](mailto:monique@lifesciadvisors.com)

---